|
|
Relationship between the 5-HTTLPR gene polymorphism and the therapeutic effect of diabetic peripheral neuropathic pain |
QIN Yong-zhang XIAO Li-xia KE Rui-qiong HONG Shi-hua LYU Wei-ming |
Department of Endocrinology and Metabolism,the First Affiliate Hospital of Gannan Medical University,Jiangxi Province,Ganzhou 341000,China |
|
|
Abstract Objective To explored the relationship between the 5-HTTLPR gene polymorphism and the therapeutic effect of Fluoxetine in the treatment of diabetic peripheral neuropathic pain.M ethods 48 patientswith diabetic peripheral neuropathic pain in ourhospital from January 2014 toMay 2015were selected and given Fluoxetine treatment for 8weeks. The PCR technology was used to examine the 5-HTTLPR gene polymorphism.Results There were 7,15 and 26 cases in L/L,L/S and S/S genotypes,respectively.The scores of SF-MPQ were(18.3±3.9)points,(22.8±4.6)points,and(25.4±5.4) points after treatment of L/L,L/S and S/S patients,compared with the scores of(45.3±5.2)points,(44.8±6.1)points and (45.7±4.9)points before treatment,respectively,with significant difference(P<0.05).The corresponding reductions of SFMPQ was(26.2±3.7)points,(21.1±4.3)points and(20.6±5.1)points,respectively,and there was significant difference between after treatment and before treatment(P<0.05).The reduction rate of L/L and L/Sgenomeweremore than 50%, and the reduction rate of L/L genotype was higher than that the other two genomes,with significant difference(P<0.01). Conclusion 5-HTTLPR gene polymorphism may be associated with the effect of Fluoxetine in the treatment of diabetic peripheral neuropathic pain.
|
|
|
|
|
[4] |
秦永章,荣海钦,季虹,等.5-HTTLPR基因多态性与2型糖尿病关联性研究[J].医学研究杂志,2011,40(7):88-90.
|
[1] |
World Health Organization.Diabetes[EB/OL].http://www.who. int/mediacentre/factsheets/fs312/en/.Accessed May 2,2009.
|
[2] |
Argoff CE,Cole BE,Fishbain DA,et al.Diabetic peripheral neuropathic pain:clinical and quality-of-life issues[A]// Mayo Clinic Proceedings[C].Elsevier,2006.
|
[3] |
李毅.度洛西汀治疗糖尿病周围神经病变性疼痛的疗效研究[D].重庆:重庆医科大学,2014.
|
[5] |
Freeman R,Durso-DeCruz E,Emir B.Efficacy,safety,and tolerability of Pregabalin treatment for painful diabetic Peripheral neuropathy findings from seven randomized,controlled trials across a range of doses[J].Diabetes Care,2008,31(7):1448-1454.
|
[6] |
孙燕霞,李淑萍.氟西汀改善脑卒中后抑郁及神经功能缺损患者的临床分析[J].齐齐哈尔医学院学报,2014,35(10):1531-1532.
|
[7] |
秦永章,柯瑞琼,肖丽霞,等.氟西汀治疗糖尿病痛性神经病变的疗效分析[J].中国现代医生,2015,53(28):53-55.
|
[8] |
秦永章,胡敬,荣海钦.5-羟色胺参与血糖调控的机制[J].中国医药指南,2010,8(24):32-35.
|
[9] |
张蕾,柯瑞琼,欧阳灿晖,等.二甲双胍联合格列美脲治疗非酒精性脂肪肝合并2型糖尿病肥胖患者的效果观察[J].中国当代医药,2016,23(20):132-134.
|
[10] |
张晓凡,李素霞,马沙.阿米替林联合α-硫辛酸治疗痛性糖尿病周围神经病变临床疗效[J].中国现代药物应用,2014,8(17):11-12.
|
[11] |
柴巧莲.5-HTTLPR与应激的交互效应对焦虑症状的预测作用[D].长沙:中南大学,2014.
|
[12] |
强晓菲.氟西汀促进脑神经功能修复的机制研究[D].石家庄:河北医科大学,2013.
|
[13] |
尹岩,刘盈,张慧杰,等.5-羟色胺转运体基因多态性与氟西汀疗效及副反应的关系[J].中国神经精神疾病杂志,2008,34(12):739-742.
|
[14] |
张鑫蕊.5-羟色胺与糖尿病周围神经病变伴发抑郁的关系[D].大连:大连医科大学,2014.
|
[15] |
Heils A,Teufel A,Petri S,et al.Allelic variation of human serotonin transporter gene expression[J].JNeurochem,1996,66(6):2621-2624.
|
|
|
|